نتائج البحث

Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn's disease patients: a retrospective multicenter study.

• Authors : Na JE; Park YE ...

Subjects: Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy ; Crohn Disease*/Crohn Disease*/Crohn Disease*/surgery ; Adalimumab*/Adalimumab*/Adalimumab*/therapeutic use

• Source: BMC gastroenterology [BMC Gastroenterol] 2024 Sep 11; Vol. 24 (1), pp. 306. Date of Electronic Publication: 2024 Sep 11.Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X

تفاصيل العنوان

Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY.

• Authors : Krugliak Cleveland N; Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA. .; Ghosh S

Subjects: Adalimumab*/Adalimumab*/Adalimumab*/therapeutic use ; Adalimumab*/Adalimumab*/Adalimumab*/adverse effects ; Infliximab*/Infliximab*/Infliximab*/therapeutic use

• Source: BMC gastroenterology [BMC Gastroenterol] 2024 Sep 17; Vol. 24 (1), pp. 314. Date of Electronic Publication: 2024 Sep 17.Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X

تفاصيل العنوان

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

• Source: An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy With Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or

تفاصيل العنوان

Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.

• Authors : Owczarek W; Department of Dermatology, Military Institute of Medicine, Warsaw, Poland.; Nowakowska A

Subjects: Adalimumab*/Adalimumab*/Adalimumab*/therapeutic use ; Psoriasis*/Psoriasis*/Psoriasis*/drug therapy ; Ustekinumab*/Ustekinumab*/Ustekinumab*/therapeutic use

• Source: Dermatologic therapy [Dermatol Ther] 2022 Jun; Vol. 35 (6), pp. e15481. Date of Electronic Publication: 2022 Apr 11.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 9700070 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab.

• Authors : Damiani G; Young Dermatologists Italian Network (YDIN), Centro Studi GISED, Bergamo, Italy.; Clinical Dermatology, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy.

Subjects: Adalimumab/Adalimumab/Adalimumab/*administration & dosage ; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*administration & dosage ; Psoriasis/Psoriasis/Psoriasis/*drug therapy

• Source: Dermatologic therapy [Dermatol Ther] 2019 Mar; Vol. 32 (2), pp. e12793. Date of Electronic Publication: 2018 Dec 21.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 9700070 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year (SEAVUE)

• Source: A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of

تفاصيل العنوان

Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.

• Authors : Maloney NJ; David Geffen School of Medicine at UCLA, Los Angeles, California.; Hisaw LD

Subjects: Adalimumab/Adalimumab/Adalimumab/*therapeutic use ; Biological Products/Biological Products/Biological Products/*therapeutic use ; Dermatologic Agents/Dermatologic Agents/Dermatologic Agents/*therapeutic use

• Source: Dermatologic therapy [Dermatol Ther] 2017 Nov; Vol. 30 (6). Date of Electronic Publication: 2017 Oct 15.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 9700070 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

TNF-Alpha Inhibitors and Ustekinumab for the Treatment of Psoriasis: Therapeutic Utility in the Era of IL-17 and IL-23 Inhibitors

• Authors : Hong, Julie J; Hadeler, Edward K; Mosca, Megan L

Subjects: Biomedical and Clinical Sciences; Clinical Sciences; Autoimmune Disease

• Source: Journal of Psoriasis and Psoriatic Arthritis. 7(2)

تفاصيل العنوان

Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis.

• Authors : Zhdanava, Maryia (AUTHOR); Kachroo, Sumesh (AUTHOR); Shah, Aditi (AUTHOR)

• Source: Patient Preference & Adherence. Apr2024, Vol. 18, p809-820. 12p.

تفاصيل العنوان

Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.

• Authors : Chen YC; Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Huang YT

Subjects: Adalimumab/Adalimumab/Adalimumab/*administration & dosage ; Etanercept/Etanercept/Etanercept/*administration & dosage ; Psoriasis/Psoriasis/Psoriasis/*drug therapy

• Source: PloS one [PLoS One] 2020 Dec 29; Vol. 15 (12), pp. e0244620. Date of Electronic Publication: 2020 Dec 29 (Print Publication: 2020).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان